---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-030236"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2026-09-14T12:59:36+00:00"
generated_at: "2026-09-14T13:00:10.944603+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Phio submits FDA briefing package for PH-762; plans Phase 2b in cutaneous squamous cell carcinoma

## Summary
- Submitted meeting request and comprehensive briefing package to FDA for PH-762, supporting next stage of clinical development.
- Phase 1b study formally completed; planned Phase 2b neoadjuvant study in cutaneous squamous cell carcinoma.
- Clinical supplies for next study expected available in Q1 2027; toxicology study dosing completed.
- Nonclinical development program and integrated clinical pharmacology data included in briefing package.

## SEC filing metadata
- accession: 0001437749-26-030236
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2026-09-14T12:59:36+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000143774926030236/0001437749-26-030236-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000143774926030236/phio20260911_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-030236
- JSON: https://secwatch.observer/filing/0001437749-26-030236.json
- Plain text: https://secwatch.observer/filing/0001437749-26-030236.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.